全文获取类型
收费全文 | 3223篇 |
免费 | 229篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 57篇 |
儿科学 | 126篇 |
妇产科学 | 92篇 |
基础医学 | 459篇 |
口腔科学 | 124篇 |
临床医学 | 306篇 |
内科学 | 620篇 |
皮肤病学 | 26篇 |
神经病学 | 258篇 |
特种医学 | 98篇 |
外科学 | 322篇 |
综合类 | 23篇 |
一般理论 | 4篇 |
预防医学 | 279篇 |
眼科学 | 59篇 |
药学 | 346篇 |
中国医学 | 1篇 |
肿瘤学 | 257篇 |
出版年
2023年 | 16篇 |
2022年 | 12篇 |
2021年 | 39篇 |
2020年 | 53篇 |
2019年 | 73篇 |
2018年 | 87篇 |
2017年 | 69篇 |
2016年 | 98篇 |
2015年 | 98篇 |
2014年 | 112篇 |
2013年 | 179篇 |
2012年 | 233篇 |
2011年 | 218篇 |
2010年 | 134篇 |
2009年 | 131篇 |
2008年 | 231篇 |
2007年 | 234篇 |
2006年 | 244篇 |
2005年 | 188篇 |
2004年 | 190篇 |
2003年 | 156篇 |
2002年 | 177篇 |
2001年 | 24篇 |
2000年 | 14篇 |
1999年 | 22篇 |
1998年 | 34篇 |
1997年 | 32篇 |
1996年 | 46篇 |
1995年 | 25篇 |
1994年 | 24篇 |
1993年 | 24篇 |
1992年 | 13篇 |
1991年 | 18篇 |
1990年 | 19篇 |
1989年 | 19篇 |
1988年 | 16篇 |
1987年 | 13篇 |
1986年 | 11篇 |
1985年 | 16篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 5篇 |
1980年 | 6篇 |
1979年 | 13篇 |
1978年 | 14篇 |
1977年 | 10篇 |
1975年 | 9篇 |
1972年 | 4篇 |
1967年 | 4篇 |
排序方式: 共有3457条查询结果,搜索用时 31 毫秒
1.
Frida Lygnegård Lena Almqvist Mats Granlund Karina Huus 《Developmental neurorehabilitation》2019,22(1):27-38
Purpose: To investigate how individual and environmental factors relate to self-reported participation profiles in adolescents with and without impairments or long-term health conditions. Methods: A person-oriented approach (hierarchical cluster analysis) was used to identify cluster groups of individuals sharing participation patterns in the outcome variables frequency perceived importance in domestic life and peer relations. Cluster groups were compared using one-way analysis of variance (ANOVA). Results: A nine-cluster solution was chosen. All clusters included adolescents with impairment and long-term health conditions. Perceived importance of peer relations was more important than frequent attendance in domestic-life activities. Frequency of participation in dialogues and family interaction patterns seemed to affect the participation profiles more than factors related to body functions. Conclusion: Type of impairment or long-term health condition is a weaker determinant of membership in clusters depicting frequency and perceived importance in domestic life or peer relations than dialogue and family environment. 相似文献
2.
3.
Wenjing Tao Miia Artama My von Euler-Chelpin Mark Hull Rickard Ljung Elsebeth Lynge Guðríður H. Ólafsdóttir Eero Pukkala Pål Romundstad Mats Talbäck Laufey Tryggvadottir Jesper Lagergren 《International journal of cancer. Journal international du cancer》2020,147(3):728-735
Obesity is a risk factor for colorectal cancer. Yet, some research indicates that weight-reducing bariatric surgery also increases colorectal cancer risk. Our study was undertaken because current evidence examining bariatric surgery and risk of colorectal cancer is limited and inconsistent. This population-based cohort study included adults with a documented obesity diagnosis in Denmark, Finland, Iceland, Norway or Sweden in 1980–2015. The incidence of colorectal cancer in participants with obesity who had and had not undergone bariatric surgery was compared to the incidence in the corresponding background population by calculating standardized incidence ratios (SIR) with 95% confidence intervals (CI). Additionally, operated and nonoperated participants with obesity were compared using multivariable Cox regression, providing hazard ratios (HR) with 95% CIs adjusted for confounders. Among 502,772 cohort participants with an obesity diagnosis, 49,931(9.9%) underwent bariatric surgery. The overall SIR of colon cancer was increased after bariatric surgery (SIR 1.56; 95% CI 1.28–1.88), with higher SIRs ≥10 years postsurgery. The overall HR of colon cancer in operated compared to nonoperated participants was 1.13 (95% CI 0.92–1.39) and 1.55 (95% CI 1.04–2.31) 10–14 years after bariatric surgery. Bariatric surgery did not significantly increase the risk of rectal cancer (SIR 1.14, 95% CI 0.83–1.52; HR 1.08, 95% CI 0.79–1.49), but the risk estimates increased with longer follow-up periods. Our study suggests that bariatric surgery is associated with an increased risk of colon cancer, while the support for an increased risk of rectal cancer was weaker. 相似文献
4.
5.
Flemming Javier Olsen MD Mats Christian Højbjerg Lassen MB Philip Brainin MD PhD Jan Bech MD PhD Alia Saed Alhakak MD Sune Pedersen MD PhD Brian Claggett PhD Thomas Fritz-Hansen MD Fredrik Folke MD PhD Gunnar H. Gislason MD PhD Tor Biering-Sørensen MD PhD MPH 《Echocardiography (Mount Kisco, N.Y.)》2020,37(11):1741-1748
6.
Shuang Lu Hong Sun Kim Yubo Cao Karan Bedi Lili Zhao Ishwarya Venkata Narayanan Brian Magnuson Yumei Gu Jing Yang Zhujun Yi Sepideh Babaniamansour Sargis Shameon Chang Xu Michelle T. Paulsen Ping Qiu Sivakumar Jeyarajan Mats Ljungman Dafydd Thomas Yali Dou Howard Crawford Marina Pasca di Magliano Kai Ge Bo Yang Jiaqi Shi 《International journal of cancer. Journal international du cancer》2023,153(3):552-570
7.
Igor Novitzky-Basso Mats Remberger Carol Chen Ivan Pasi Wilson Lam Arjun Law Armin Gerbitz Auro Viswabandya Jeffrey H. Lipton Dennis D. Kim Rajat Kumar Jonas Mattsson Fotios V. Michelis 《European journal of haematology》2022,108(1):61-72
During 2020, the concurrent novel COVID-19 pandemic lead to widespread cryopreservation of allogeneic hematopoietic cell transplant grafts based on National Marrow Donor Program and European Society of Blood and Marrow Transplantation recommendations, in order to secure grafts before the start of conditioning chemotherapy. We sought to examine the impact of this change in practice on patient outcomes. We analyzed the outcomes of 483 patients who received hematopoietic stem cell transplantation (HSCT) between August 2017 and August 2020, at Princess Margaret Cancer Centre, Canada, in the retrospective study, comparing the outcomes between those who received cryopreserved or fresh peripheral blood stem cell grafts. Overall compared with those who received fresh grafts (n = 348), patients who received cryopreserved grafts (n = 135) had reduced survival and GRFS, reduced incidence of chronic graft-versus-host disease (GvHD), delay in neutrophil engraftment, and higher graft failure (GF), with no significant difference in relapse incidence or acute GvHD. However, recipients of cryopreserved matched-related donor HSCT showed significantly worse OS, NRM, GRFS compared with fresh grafts. Multivariable analysis of the entire cohort showed significant impact of cryopreservation on OS, relapse, cGvHD, GF, and GRFS. We conclude that cryopreservation was associated with inferior outcomes post-HSCT, possibly due to the combination of ATG and post-transplant cyclophosphamide impacting differential tolerance to cryopreservation on components of the stem cell graft; further studies are warranted to elucidate mechanisms for this observation. 相似文献
8.
Maria Sjöberg Mats Eriksson Josefin Andersson Torbjörn Norén 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2014,122(9):800-803
The aim of this study was to determine the dissemination of Clostridium difficile (CD) spores in a hospital setting where the potassium monopersulfate‐based disinfectant VirkonTM was used for cleaning. In the initial part of the study, we sampled 16 areas of frequent patient contact in 10 patient rooms where a patient with CD infection (CDI) had been accommodated. In the second part of the study, we obtained samples from 10 patient beds after discharge of CDI patients, both before and after the beds were cleaned. In the first part, CDspores were isolated in only 30% of the rooms. In the second part, which focused on transmission to hospital beds, C. difficile was found in four of 10 beds either before or after cleaning. In conclusion, in both parts of the study, we demonstrated a moderate spread of CD spores to the environment despite routine cleaning procedures involving VirkonTM. 相似文献
9.
Olle Muren Ehsan Akbarian Mats Salemyr Henrik Bodén Thomas Eisler André Stark Olof Sk?ldenberg 《Acta orthopaedica》2015,86(5):569-574
Background and purpose
We have previously shown that during the first 2 years after total hip arthroplasty (THA), periprosthetic bone resorption can be prevented by 6 months of risedronate therapy. This follow-up study investigated this effect at 4 years.Patients and methods
A single-center, double-blind, randomized placebo-controlled trial was carried out from 2006 to 2010 in 73 patients with osteoarthritis of the hip who were scheduled to undergo THA. The patients were randomly assigned to receive either 35 mg risedronate or placebo orally, once a week, for 6 months postoperatively. The primary outcome was the percentage change in bone mineral density (BMD) in Gruen zones 1 and 7 in the proximal part of the femur at follow-up. Secondary outcomes included migration of the femoral stem and clinical outcome scores.Results
61 of the 73 patients participated in this 4-year (3.9- to 4.1-year) follow-up study. BMD was similar in the risedronate group (n = 30) and the placebo group (n = 31). The mean difference was −1.8% in zone 1 and 0.5% in zone 7. Migration of the femoral stem, the clinical outcome, and the frequency of adverse events were similar in the 2 groups.Interpretation
Although risedronate prevents periprosthetic bone loss postoperatively, a decrease in periprosthetic BMD accelerates when therapy is discontinued, and no effect is seen at 4 years. We do not recommend the use of risedronate following THA for osteoarthritis of the hip.Adaptive bone remodeling around the femoral stem following total hip arthroplasty (THA) results in regional loss of bone mass, especially in proximal parts of the femur—most of which takes place within the first postoperative year (Bodén et al. 2006, Sköldenberg et al. 2006). Periprosthetic bone loss may predispose to periprosthetic fracture, aseptic loosening, and difficulties at revision surgery (Lindahl 2007, Streit et al. 2011, Sköldenberg et al. 2014).The bisphosphonate (BP) risedronate has been used successfully to prevent osteoporotic fractures, mainly in the hip and vertebrae, by inhibiting osteoclast activity (McClung et al. 2001). In recent years, the possible use of BPs to prevent or ameliorate periprosthetic adaptive bone resorption, osteolysis, and implant migration has been investigated thoroughly in animal models and humans. The short-term results of several studies showing the effects of postoperative BP treatment in reducing periprosthetic bone loss up to a year after the arthroplasty have already been published (Venesmaa et al. 2001, Wilkinson et al. 2001, Hennigs et al. 2002, Wilkinson et al. 2005, Arabmotlagh et al. 2006).We have previously found that risedronate given once a week for 6 months after THA reduces periprosthetic bone resorption around an uncemented femoral stem in the first and second postoperative year (Sköldenberg et al. 2011). We now report the 4-year outcome in the same cohort. 相似文献10.